Delilah Alvarado

Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.

The Series B round will fund a Phase 1/2 trial of the company's experimental treatment for IgA nephropathy.

The company has set high expectations for depemokimab, which it is also advancing in three other inflammatory diseases, including asthma.

The amount surpassed the firm's targets, allowing it to increase the size and number of company financings it plans to do in the future.

The hold, which was made in response to a serious adverse event report, could impact the company’s plans to start a Phase 3 trial of a combination shot for COVID-19 and influenza.

The company's leadership is also being reshuffled, with five senior executives departing and others taking their place.

Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval by the 2025-2026 season.

Under the proposed deal, the PE firm would take a controlling 50% stake in Sanofi’s Opella unit, with state-owned Bpifrance taking a minority 2% position.

The shot, which Pfizer sells as Abrysvo, is now approved in adults aged 18 to 59 years old who are at increased risk of disease. Dive Brief:

Sanofi and partner AstraZeneca recently increased production capacity for their RSV antibody shot, sales of which jumped during the third quarter.